New Paradigms for Treatment-resistant Depression

Overview

Journal Ann N Y Acad Sci

Specialty Science

Date 2013 Jul 24

PMID 23876043

Citations 44

Authors

Carlos Zarate

Ronald S Duman

Guosong Liu

Simone Sartori

Jorge Quiroz

Harald Murck

Affiliations

Soon will be listed here.

Abstract

Clinical depression is a serious mental disorder characterized by low mood, anhedonia, loss of interest in daily activities, and other symptoms, and is associated with severe consequences including suicide and increased risk of cardiovascular events. Depression affects nearly 15% of the population. The standard of care for the last 50 years has focused on monoamine neurotransmitters, including such treatments as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). However, these treatments have significant limitations: they can take weeks before showing mood-altering effects, and only one to two out of ten patients shows clinical effects beyond those associated with placebo. A major paradigm shift in research into the treatment of depression is underway, based on promising results with the glutamatergic NMDA receptor antagonist ketamine. Further research has demonstrated the significance of glutamatergic pathways in depression and the association of this system with the stress pathway and magnesium homeostasis. Treatment with NMDA receptor antagonists and magnesium have shown the ability to sprout new synaptic connections and reverse stress-induced neural changes, opening up promising new territory for the development of drugs to meet the unmet need in patients with clinical depression.

Citing Articles

Transdermal Scopolamine for Treatment-Resistant Major Depressive Disorder.

Liester M, Shash D Cureus. 2024; 16(9):e68447.

PMID: 39360115 PMC: 11446176. DOI: 10.7759/cureus.68447.

Progress and trends of research on mineral elements for depression.

Gao B, Li C, Qu Y, Cai M, Zhou Q, Zhang Y Heliyon. 2024; 10(15):e35469.

PMID: 39170573 PMC: 11336727. DOI: 10.1016/j.heliyon.2024.e35469.

Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis.

Wang X, Zhu X, Ji X, Yang J, Zhou J Neuropsychiatr Dis Treat. 2023; 19:1043-1053.

PMID: 37153351 PMC: 10162387. DOI: 10.2147/NDT.S408794.

A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression.

Can A, Hermens D, Lagopoulos J Clin Case Rep. 2022; 10(12):e6675.

PMID: 36523376 PMC: 9748241. DOI: 10.1002/ccr3.6675.

HisT is a specific histamine transporter that contributes to histamine recycling in glia.

Xie J, Han Y, Liang Y, Peng L, Wang T Sci Adv. 2022; 8(43):eabq1780.

PMID: 36288320 PMC: 9604546. DOI: 10.1126/sciadv.abq1780.

References

Homayoun H, Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27(43):11496-500. PMC: 2954603. DOI: 10.1523/JNEUROSCI.2213-07.2007. View

Paul I, Skolnick P . Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003; 1003:250-72. DOI: 10.1196/annals.1300.016. View

Hyman S . Revolution stalled. Sci Transl Med. 2012; 4(155):155cm11. DOI: 10.1126/scitranslmed.3003142. View

Reus G, Stringari R, Ribeiro K, Ferraro A, Vitto M, Cesconetto P . Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res. 2011; 221(1):166-71. DOI: 10.1016/j.bbr.2011.02.024. View

Sartori S, Whittle N, Hetzenauer A, Singewald N . Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology. 2011; 62(1):304-12. PMC: 3198864. DOI: 10.1016/j.neuropharm.2011.07.027. View

Teyssier J, Ragot S, Chauvet-Gelinier J, Trojak B, Bonin B . Activation of a ΔFOSB dependent gene expression pattern in the dorsolateral prefrontal cortex of patients with major depressive disorder. J Affect Disord. 2011; 133(1-2):174-8. DOI: 10.1016/j.jad.2011.04.021. View

Rowland L, Bustillo J, Mullins P, Jung R, Lenroot R, Landgraf E . Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005; 162(2):394-6. DOI: 10.1176/appi.ajp.162.2.394. View

Dwivedi Y, Rao J, Rizavi H, Kotowski J, Conley R, Roberts R . Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003; 60(3):273-82. DOI: 10.1001/archpsyc.60.3.273. View

Burgdorf J, Zhang X, Nicholson K, Balster R, Leander J, Stanton P . GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013; 38(5):729-42. PMC: 3671991. DOI: 10.1038/npp.2012.246. View

10.

Li N, Lee B, Liu R, Banasr M, Dwyer J, Iwata M . mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329(5994):959-64. PMC: 3116441. DOI: 10.1126/science.1190287. View

11.

Chatterjee M, Verma R, Ganguly S, Palit G . Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology. 2012; 63(6):1161-71. DOI: 10.1016/j.neuropharm.2012.05.041. View

12.

Huang C, Liou Y, Chung S, Lin W, Jong G, Kuo C . Role of ERK signaling in the neuroprotective efficacy of magnesium sulfate treatment during focal cerebral ischemia in the gerbil cortex. Chin J Physiol. 2011; 53(5):299-309. DOI: 10.4077/cjp.2010.amk063. View

13.

Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D . Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4):351-4. DOI: 10.1016/s0006-3223(99)00230-9. View

14.

Murck H . Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back. J Psychiatr Res. 2013; 47(7):955-65. DOI: 10.1016/j.jpsychires.2013.02.015. View

15.

Zarate Jr C, Brutsche N, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A . Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012; 71(11):939-46. PMC: 3343177. DOI: 10.1016/j.biopsych.2011.12.010. View

16.

Yamada S, Yamamoto M, Ozawa H, Riederer P, Saito T . Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm (Vienna). 2003; 110(6):671-80. DOI: 10.1007/s00702-002-0810-8. View

17.

Slutsky I, Sadeghpour S, Li B, Liu G . Enhancement of synaptic plasticity through chronically reduced Ca2+ flux during uncorrelated activity. Neuron. 2004; 44(5):835-49. DOI: 10.1016/j.neuron.2004.11.013. View

18.

Maurizi M, Pinkofsky H, McFarland P, Ginsburg A . Mg2+ is bound to glutamine synthetase extracted from bovine or ovine brain in the presence of L-methionine-S-sulfoximine phosphate. Arch Biochem Biophys. 1986; 246(1):494-500. DOI: 10.1016/0003-9861(86)90496-0. View

19.

Liu G . Local structural balance and functional interaction of excitatory and inhibitory synapses in hippocampal dendrites. Nat Neurosci. 2004; 7(4):373-9. DOI: 10.1038/nn1206. View

20.

Singewald N, Sinner C, Hetzenauer A, Sartori S, Murck H . Magnesium-deficient diet alters depression- and anxiety-related behavior in mice--influence of desipramine and Hypericum perforatum extract. Neuropharmacology. 2004; 47(8):1189-97. DOI: 10.1016/j.neuropharm.2004.08.010. View